SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with
Hemophilia A or B with inhibitors aged 12 to 65 years, inclusive, who are either on long term
prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding
event (BE), or who are not on prophylactic treatment who may need to control a BE.